Dr. Mark Boulos explains more in this 'behind the research' feature
Read full story
Research news
Wednesday, October 13, 2021 Sunnybrook researchers demonstrate groundbreaking evidence of focused ultrasound enhanced delivery of targeted antibody therapy to breast cancer that spread to the brain
Research team captured world-first images of the antibody therapy drug, Trastuzumab, precisely targeting tumours which spread to the brain from breast cancer, across the blood-brain barrier
Read full story
Research team captured world-first images of the antibody therapy drug, Trastuzumab, precisely targeting tumours which spread to the brain from breast cancer, across the blood-brain barrier
Read full story
Tuesday, October 12, 2021 How at-home sleep tests can help diagnose sleep apnea in patients with stroke
Dr. Mark Boulos explains more in this 'behind the research' feature
Read full story
Dr. Mark Boulos explains more in this 'behind the research' feature
Read full story
Tuesday, October 12, 2021 New commentary in Nature Medicine explores placebo effects in clinical trials
Dr. Matthew Burke explains what this means for the future of clinical trials
Read full story
Dr. Matthew Burke explains what this means for the future of clinical trials
Read full story
Wednesday, September 15, 2021 Dr. Sandra Black recognized with national award for excellence in brain research
Dr. Black has been awarded this year's Margolese National Brain Disorders Prize from the University of British Columbia
Read full story
Dr. Black has been awarded this year's Margolese National Brain Disorders Prize from the University of British Columbia
Read full story
Thursday, September 9, 2021 Major study finds convalescent plasma doesn’t help seriously ill COVID-19 patients
The CONCOR-1 clinical trial stopped enrolment early in January 2021 after its independent data safety monitoring committee recommended the study was unlikely to demonstrate a benefit of convalescent plasma even if more patients were enrolled.
Read full story
The CONCOR-1 clinical trial stopped enrolment early in January 2021 after its independent data safety monitoring committee recommended the study was unlikely to demonstrate a benefit of convalescent plasma even if more patients were enrolled.
Read full story
